WHO Says Bundibugyo Ebola Vaccine Trials Are 6-9 Months Away Amid 50 Confirmed Cases
Updated
Updated · NBC News · May 20
WHO Says Bundibugyo Ebola Vaccine Trials Are 6-9 Months Away Amid 50 Confirmed Cases
15 articles · Updated · NBC News · May 20
Two Bundibugyo Ebola vaccine candidates exist, but WHO said neither is ready for human testing and the stronger prospect needs 6-9 months to produce enough trial doses.
A second candidate could be available in 2-3 months, but it still lacks supportive animal data, leaving no assurance any vaccine will work against the strain driving outbreaks in Congo and Uganda.
Merck’s Ervebo is under review as a stopgap, yet WHO said it is not a Bundibugyo vaccine and limited macaque data suggest protection may be only about 50%.
With no approved shot, responders are relying on contact tracing, isolation and infection-control measures against a rarer Ebola strain that typically kills about 25%-40% of patients.
Can new mRNA vaccine technology be deployed fast enough to stop this rare Ebola outbreak in its tracks?
Why must an outbreak start before vaccines are developed for known deadly viruses like the Bundibugyo Ebola strain?
With a rare Ebola virus spreading in a conflict zone, can traditional containment strategies succeed?
Bundibugyo Virus Disease Outbreak 2026: 32 Cases, No Vaccine, and Cross-Border Threats in Central Africa
Overview
In May 2026, a deadly outbreak of Bundibugyo virus disease (BVD), a type of Ebola, was first detected in Ituri Province, Democratic Republic of Congo, after health workers reported a high-mortality illness. The World Health Organization was alerted on May 5, and by May 14, laboratory tests confirmed BVD in blood samples from the region. Results became available on May 15, and by May 20, there were 32 confirmed cases in the DRC. This rapid identification and confirmation process highlights the urgent response needed to contain the outbreak and protect both local communities and health workers.